BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.6364.

A number of research firms have recently weighed in on BCRX. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th. Citizens Jmp lowered their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, November 5th. Evercore initiated coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price on the stock. Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Barclays lowered their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th.

Insider Activity at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $7.10, for a total value of $646,128.40. Following the sale, the insider directly owned 416,152 shares in the company, valued at approximately $2,954,679.20. This trade represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold 183,453 shares of company stock worth $1,330,965 over the last three months. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

A number of large investors have recently modified their holdings of BCRX. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the last quarter. RA Capital Management L.P. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $123,452,000. Deerfield Management Company L.P. increased its stake in shares of BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the period. State Street Corp raised its holdings in shares of BioCryst Pharmaceuticals by 12.9% during the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after buying an additional 1,265,773 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after buying an additional 7,310,745 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

Key BioCryst Pharmaceuticals News

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings materially beat expectations: GAAP EPS $1.12 vs. consensus $0.07 and revenue $163.3M (up ~209% YoY), signaling improved profitability and top‑line momentum. BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Strong full‑year ORLADEYO revenue: FY‑2025 net sales of $601.8M (+38% y/y) underpin recurring product cash flow and support commercialization progress. BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Astria acquisition expands BioCryst’s HAE franchise and prompted an immediate bullish market reaction; management says the deal supports guidance and HAE portfolio scale. BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance
• Neutral Sentiment: Market commentary and valuation pieces are assessing whether the post‑beat rebound leaves BCRX fairly valued; these pieces summarize upside vs. execution risks for investors doing further due diligence. Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound
• Neutral Sentiment: Management hosted a conference call and published the slide deck and press release; review the materials for guidance details and pipeline commentary that could matter for forward estimates. View Press Release / Slide Deck
• Negative Sentiment: Despite the GAAP beat, reported net margin and return on equity remain slightly negative, and some analysts still forecast a modest FY loss — keep an eye on guidance and margin trajectory. BioCryst Q4 earnings and metrics (MarketBeat)
• Negative Sentiment: Reported short‑interest data for February is inconsistent/odd in public feeds (zero/NaN entries), but any material rise in shorts would be a bearish technical headwind — monitor reliable short‑interest releases for clarity. BioCryst: Q4 Earnings Snapshot

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.90 on Friday. The firm has a 50-day moving average of $7.11 and a two-hundred day moving average of $7.40. The stock has a market cap of $1.66 billion, a P/E ratio of -158.00 and a beta of 0.83. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $1.05. The business had revenue of $163.28 million for the quarter, compared to analyst estimates of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The company’s revenue for the quarter was up 209.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.13) earnings per share. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.